It targets patients with chronic inflammatory diseases, with primary customers expected to be healthcare providers, hospitals, and specialty clinics treating atopic dermatitis and COPD.Was the transaction price aligned with prevailing market levels? The weighted average sale price was around $77.84 per share, closely matching the Wednesday market close of$78.95, reflecting execution near the prevailing price level on that date.What is Dambkowski’s remaining equity exposure after this transaction? Dambkowsk ...